Advanced search
Publication Cover
Hematology Volume 21, 2016 - Issue 7
Submit an article Journal homepage
1,246
Views
14
CrossRef citations to date
0
Altmetric
Hematological Malignancy

Early mortality in multiple myeloma: Experiences from a single institution

Yeh-Ku ChenDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan
,
Shao-Min HanDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan
,
Youngsen YangDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan;School of Medicine, College of Medicine, China Medical University, Taiwan
,
Tseng-Hsi LinDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan;Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taiwan;Department of Medicine, Chung Shan Medical University, Taiwan
,
Huey-En TzengDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan
,
Kuang-Hsi ChangDepartment of Medical Research and Education, Taichung Veterans General Hospital, Taiwan
,
Wen-Li HwangDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, TaiwanCorrespondence[email protected]
&
Chieh-Lin Jerry TengDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taiwan;Department of Medicine, Chung Shan Medical University, Taiwan;Department of Life Science, Tunghai University, TaiwanCorrespondence[email protected]
 show all
Pages 392-398 | Published online: 16 Feb 2016

References

  • Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–72. doi: 10.1182/blood-2007-10-078022
  • Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. doi: 10.1182/blood-2007-10-116129
  • Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. New Engl J Med. 2003;349:2495–502. doi: 10.1056/NEJMoa032290
  • Mateos MV, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program. 2013;2013:488–95. doi: 10.1182/asheducation-2013.1.488
  • Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219–26. doi: 10.1200/JCO.2005.03.2086
  • Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8. doi: 10.1038/leu.2013.313
  • Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009;84:1095–110. doi: 10.4065/mcp.2009.0603
  • Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259–66. doi: 10.1200/JCO.2009.26.0638
  • Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767–72.
  • Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100:624–8. doi: 10.1016/S0002-9343(95)00043-7
  • Jung SH, Kang SJ, Jang HC, Ahn JS, Yang DH, Lee SS, et al. Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. Int J Hematol. 2014;100:473–7. doi: 10.1007/s12185-014-1672-1
  • Friese CR, Abel GA, Magazu LS, Neville BA, Richardson LC, Earle CC. Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma. 2009;50:392–400. doi: 10.1080/10428190902741471
  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med. 2008;359:906–17. doi: 10.1056/NEJMoa0801479
  • Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib–melphalan–prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 2014;99:1114–22. doi: 10.3324/haematol.2013.099341
  • Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101–9. doi: 10.1200/JCO.2010.29.8216
  • Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784–8. doi: 10.3324/haematol.2012.074534
  • Huang TC, Chen JH, Wu YY, Chang PY, Dai MS, Chao TY, et al. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation – a single institutional experience in Taiwan. Ann Hematol. 2015;94:107–15. doi: 10.1007/s00277-014-2165-2
  • Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011;94:310–20. doi: 10.1007/s12185-011-0947-z

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.